The 30 most recent market catalysts affecting $AMGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
Amgen reported encouraging topline results for dazodalibep in its Phase 3 OASIZ 301 study for Sjögren's disease, a significant milestone given the historical difficulties in SjD dr…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Amgen shares are trading higher after the company announced the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity met its primary endpoint.
This headline represents a significant positive catalyst for Amgen. Successful Phase 3 clinical trials are crucial milestones in drug development, de-risking future revenue potenti…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Amgen Announces Its Phase 3 OASIZ 301 Trial Of Dazodalibep To Treat Sjogren's Disease Meets Primary Endpoint, Shows Improvement In Systemic Disease Activity At Week 48
Amgen announced that its Phase 3 OASIZ 301 trial for dazodalibep, targeting Sjögren's disease, successfully met its primary endpoint. This is a significant development as it indica…
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 65
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425
HSBC analyst Morten Herholdt downgraded Amgen from a 'Buy' to a 'Hold' rating and lowered the price target from $445 to $425. This action signals a reduced confidence in Amgen's fu…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 75
What's Going On With Amgen Stock Tuesday?
Novartis's pelacarsen, an Lp(a)-lowering drug, failed its Phase 3 trial to reduce major cardiovascular events. This is significant because Amgen is developing olpasiran, another Lp…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Amgen shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint, with investors assessing the impact on AMGN's olpasiran phase III study. Also, BMO Capital downgraded its rating on the stock from Outperform to Market Perform and maintained its $450 price target.
The headline presents a significant corporate catalyst for Amgen, driven by a negative read-across from a competitor's failed drug trial. The 'sympathy' selling indicates investor …
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 55
BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450
BMO Capital's downgrade of Amgen from 'Outperform' to 'Market Perform' signals a shift in the analyst's confidence regarding the stock's future performance relative to the broader …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Amgen Says Repatha Cut Death Risk By 20% In High-Risk Heart Patients
Amgen reported that its drug Repatha significantly reduced the risk of death by 20% in high-risk heart patients without a prior heart attack or stroke. This is a major positive dev…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Amgen and AstraZeneca reported that their co-developed drug, TEZSPIRE, successfully met both co-primary and all key secondary endpoints in the Phase 3 CROSSING trial for Eosinophil…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457
Piper Sandler analyst David Amsellem has maintained an 'Overweight' rating on Amgen and raised the price target from $427 to $457. This action signals increased confidence from the…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
Amgen shares are trading higher after Argus Research raised its price target on the stock from $375 to $460.
The analyst upgrade from Argus Research, raising Amgen's price target by a substantial margin, acts as a strong positive catalyst for the stock. This indicates that the research fi…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 55
Argus Research Maintains Buy on Amgen, Raises Price Target to $460
Argus Research analyst Jasper Hellweg maintained a 'Buy' rating on Amgen and significantly raised the price target from $375 to $460. This upgrade reflects a more optimistic view o…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Neutral on Amgen, Raises Price Target to $352
Mizuho analyst Salim Syed has maintained a 'Neutral' rating on Amgen (AMGN) but significantly increased the price target from $303 to $352. This action indicates that while the ana…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $380
Barclays analyst Emily Field maintained an 'Equal-Weight' rating on Amgen but raised the price target from $360 to $380. This action signals a modest increase in the analyst's valu…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Reported Earlier, Amgen To Open New Science And Innovation Center At Genome Valley In Hyderabad
Amgen is expanding its global Research and Development network by opening a new science and innovation center in Genome Valley, Hyderabad, India, slated for 2027. This move is sign…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 65
Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
The filing details three companies that were recommended on CNBC's 'Final Trades' segment, primarily due to their recent strong earnings reports. Chubb and Toast both beat earnings…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 55
CNBC Halftime Report Final Trades: Amgen, Toast, Chubb
The headline signals that these three stocks were featured as 'final trades' on a popular financial news program, implying they were recommended for short-term action by panelists.…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Bernstein Maintains Market Perform on Amgen, Raises Price Target to $345
Bernstein analyst Courtney Breen maintained a 'Market Perform' rating on Amgen but raised the price target from $335 to $345. This indicates that while the analyst sees some upside…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Amgen, Raises Price Target to $440
UBS analyst Michael Yee maintained a 'Buy' rating on Amgen and raised the price target from $420 to $440. This action signals an analyst's continued positive outlook on Amgen's fin…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Amgen, Raises Price Target to $452
TD Cowen analyst Yaron Werber maintained a 'Buy' rating on Amgen and raised the price target from $420 to $452. This indicates a positive outlook from a prominent financial institu…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $450
Oppenheimer analyst Jay Olson maintained an 'Outperform' rating on Amgen and raised the price target from $400 to $450. This action signals increased confidence in Amgen's future p…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $450
Scotiabank analyst Louise Chen has maintained a 'Sector Outperform' rating on Amgen and raised the price target from $385 to $450. This action signals increased confidence from the…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Amgen, Raises Price Target to $400
RBC Capital's analyst Luca Issi has raised the price target for Amgen (AMGN) from $370 to $400 while maintaining an Outperform rating. This action signals increased confidence from…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
Amgen shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY26 adjusted EPS guidance with its midpoint above estimates and raised its FY26 sales guidance above estimates. Also, BMO Capital maintained its Outperform rating and raised its price target from $400 to $450.
This headline is a major positive catalyst for Amgen. Better-than-expected earnings and, more importantly, significantly raised long-term guidance (FY26 EPS and sales) signal stron…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
BMO Capital Maintains Outperform on Amgen, Raises Price Target to $450
BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Amgen and raised the price target from $400 to $450. This action signals a strengthened conviction…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Increase In Operating Expenses In Q3
Amgen's disclosure of $500 million in Q2 capital expenditures and the reaffirmation of $2.6 billion in capex for 2026 signals significant investment in manufacturing infrastructure…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 65
Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity
Amgen has decided to cease future development of AMG 513, an obesity drug candidate. This is significant because it removes a potential future revenue stream and growth driver from…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 92
Amgen Q2 Adj. EPS $6.29 Beats $5.62 Estimate, Sales $10.054B Beat $9.421B Estimate
Amgen's Q2 results show a substantial beat on both adjusted EPS and sales estimates, with earnings up 4.49% year-over-year and sales up 9.53%. This indicates strong underlying busi…
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 65
Amgen Disagrees With FDA Proposal To Withdraw TAVNEOS From U.S. Market; Submitted Data And Analyses To FDA To Request Hearing On TAVNEOS
Amgen has publicly stated its disagreement with the FDA's proposal to withdraw TAVNEOS (avacopan) from the U.S. market. The company has submitted comprehensive data and analyses to…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Amgen, Raises Price Target to $420
UBS analyst Michael Yee has updated his outlook on Amgen, raising the price target from $400 to $420 while keeping a 'Buy' rating. This action indicates a continued positive sentim…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.